

**Cancer League of Colorado
2019 Research Grants Awarded**

PRINCIPAL INVESTIGATOR	TITLE OF PROJECT	AMOUNT AWARDED
Adam Mueller, MD, PhD	Investigating crosstalk between ADAM10 and EphrinB2/EPHB4 in mediating radiation induced fibrosis, invasion and metastasis in pancreatic cancer	\$ 30,000
Cem Altunbas, PhD	High-fidelity volumetric imaging for quantitative treatment monitoring and modifications in radiation therapy	\$ 30,000
Heather Brechbuhl, PhD	Defining reversible tumor traits in the obese microenvironment	\$ 30,000
Isabel Schlaepfer, PhD	Role of fat oxidation via CPT1A in immunological response to prostate cancer	\$ 30,000
Jay Hesselberth, PhD	Single-cell methods to measure functional heterogeneity	\$ 30,000
John Tentler, PhD	Cancer Research Summer Fellowship Program	\$ 30,000
Matthew Sikora, PhD	Defining MDC1 as a central regulator of estrogen receptor and DNA repair in lobular carcinoma	\$ 30,000
Mayumi Fujita, MD, PhD & Donald Backos, PhD	Somatic mutations in inflammasome genes in melanoma	\$ 60,000
Neelanjan Mukherjee, PhD & Daniel Sherbenou, MD, PhD	Exploiting mRNA translation inhibition for the treatment of relapsed/refractory multiple myeloma	\$ 60,000
Neil Box, PhD	Regulation of p53 in tanning	\$ 30,000
Paul Norman, PhD	Natural Killer cells can protect from developing leukemia	\$ 30,000
Rajeev Vibhakar, MD, PhD, MPH	Role of CDK7 in medulloblastoma	\$ 30,000
Carol Sartorius, PhD	PR-RAR downregulation of protein synthesis and cell growth in breast cancer	\$ 30,000

Shi-Long Lu, MD, PhD and Daniel Frank, PhD	Mechanism of oral microbiota in head and neck cancer pathogenesis and application for targeted therapy	\$ 60,000
Stephen Keysar, PhD	Targeting of stemness factors and fusion proteins in salivary gland cancers through inhibition of translation elongation	\$ 30,000
Sujatha Venkataraman, PhD and Mark Kohler, MD, PhD	CD99 targeting CAR T cells as a novel therapy for H3K27M mutant DIPG	\$ 60,000
Yiqun Shellman, PhD & Martin McCarter, MD	Targeting anti-apoptotic pathways to improve immunotherapies for melanoma	\$ 60,000
Zachary Levi Watson, PhD	Targeting histone acetylation in PARP inhibitor-resistant ovarian cancer	\$ 30,000
		\$ 690,000